FT - 1518

 A highly selective mTOR inhibitor that has shown remarkable preclinical characteristics

How it works

mTOR, mammalian target of rapamycin, pathway is a key driver of cancer cell growth, survival, invasion, drug resistance and tumor vascularization.  The mTOR pathway is also the key mediator and activator in the PI3K/AKT pathway and contains two primary complexes, mTORC1 and mTORC2.  FT-1518 works by selectively targeting both mTORC1 and mTORC2 while avoiding the PI3K pathway.   

Selectivity

FT - 1518 selectively targets both mTOR complexes, demonstrating a potency that enables greater efficacy with limited immunosuppression and toxicities.  This selectivity has shown a strong p450 profile in preclinical testing making it a candidate for possible combination therapies. 

Competitive advantage 

When compared to other mTOR inhibitors currently in first-in-human testing, FT-1518 has shown a structural advantage for synthesis, less potential off-target toxicity, and an ability to avoid DNA-protein kinase further differentiating itself from any potential competitors.